Drug
Leo 29102
Leo 29102: highest development phase Phase 2, developed by LEO Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| LEO 29102 NCT01037881 | Phase 2 | Atopic Dermatitis |
| LEO 29102 NCT01423656 | Phase 1 | Atopic Dermatitis |
Latest
No recent events.
Follow Leo 29102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.